 |
 |

Randomized Clinical Trial of Treatments for Symptomatic Convergence Insufficiency in Children
Convergence Insufficiency Treatment Trial Study Group*
Arch Ophthalmol. 2008;126(10):1336-1349.
Objective To compare home-based pencil push-ups (HBPP), home-based computer vergence/accommodative therapy and pencil push-ups (HBCVAT+), office-based vergence/accommodative therapy with home reinforcement (OBVAT), and office-based placebo therapy with home reinforcement (OBPT) as treatments for symptomatic convergence insufficiency.
Methods In a randomized clinical trial, 221 children aged 9 to 17 years with symptomatic convergence insufficiency were assigned to 1 of 4 treatments.
Main Outcome Measures Convergence Insufficiency Symptom Survey score after 12 weeks of treatment. Secondary outcomes were near point of convergence and positive fusional vergence at near.
Results After 12 weeks of treatment, the OBVAT group's mean Convergence Insufficiency Symptom Survey score (15.1) was statistically significantly lower than those of 21.3, 24.7, and 21.9 in the HBCVAT+, HBPP, and OBPT groups, respectively (P < .001). The OBVAT group also demonstrated a significantly improved near point of convergence and positive fusional vergence at near compared with the other groups (P .005 for all comparisons). A successful or improved outcome was found in 73%, 43%, 33%, and 35% of patients in the OBVAT, HBPP, HBCVAT+, and OBPT groups, respectively.
Conclusions Twelve weeks of OBVAT results in a significantly greater improvement in symptoms and clinical measures of near point of convergence and positive fusional vergence and a greater percentage of patients reaching the predetermined criteria of success compared with HBPP, HBCVAT+, and OBPT.
Application to Clinical Practice Office-based vergence accommodative therapy is an effective treatment for children with symptomatic convergence insufficiency.
Trial Registration clinicaltrials.gov Identifier: NCT00338611
*Authors/Writing Committee: The following members of the Convergence Insufficiency Treatment Trial Study Group take authorship responsibility for the results: Lead authors: Mitchell Scheiman, OD; Susan Cotter, OD, MS; G. Lynn Mitchell, MAS; Marjean Kulp, OD, MS; Michael Rouse, OD, MEd; Richard Hertle, MD; and Maryann Redford, DDS, MPH. Additional writing committee members (alphabetical): Jeffrey Cooper, MS, OD; Rachel Coulter, OD; Michael Gallaway, OD; David Granet, MD; Kristine Hopkins, OD, MSPH; Brian G. Mohney, MD; and Susanna Tamkins, OD.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Response to Editorial About the Convergence Insufficiency Treatment Trial--Reply
Wallace
Arch Ophthalmol 2009;127:1230-1231.
FULL TEXT
Response to Editorial About the Convergence Insufficiency Treatment Trial
Cotter et al.
Arch Ophthalmol 2009;127:1229-1230.
FULL TEXT
Learning Disabilities, Dyslexia, and Vision
American Academy of Pediatrics, Section on Ophthal et al.
Pediatrics 2009;124:837-844.
ABSTRACT
| FULL TEXT
Effectiveness of Placebo Therapy for Maintaining Masking in a Clinical Trial of Vergence/Accommodative Therapy
Kulp et al.
IOVS 2009;50:2560-2566.
ABSTRACT
| FULL TEXT
Does Nonsurgical Treatment of Exodeviations Work?
Karlsson
Amer. Orthoptic Jrnl. 2009;59:18-25.
ABSTRACT
Treatment Options for Symptomatic Convergence Insufficiency
Wallace
Arch Ophthalmol 2008;126:1455-1456.
FULL TEXT
|